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ATTENUATION OF ISCHEMIC LIVER INJURY BY 
AUGMENTATION OF ENDOGENOUS ADENOSINE1,2 
SATORU TODo,3 YUE ZHU, SHIMIN ZHANG, MAENG BONG JIN, NAOKI ISHIZAKI, HmoMU TANAKA, 
VLADIMIR SUBBOTIN, AND THOMAS E. STARZL 
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Hepatic grafts from non-heartbeating donors may 
alleviate the organ shortage, but they inherently suf-
fer from warm ischemia. In the present study, we 
tested our hypothesis that augmentation of endoge-
nous adenosine by inhibition of nucleoside transport 
with R75231 attenuates ischemic liver injury. Adult 
female beagle dogs underwent 2·hr hepatic vascular 
exclusion with venovenous bypass. R75231 was given 
to the animals by continuous intravenous infusion for 
30 min before ischemia at a dose of 0.1 mg/kg (Group 2, 
n=6), 0.05 mg/kg (Group 3, n=6), or 0.025 mg/kg (Group 
4, n=6). Nontreated animals were used as the control 
(Group 1, n=10). Animal survival, hepatic tissue blood 
tlow, liver function, and histopathology were ana-
lyzed. Two-week animal survival was 300/0 in Group 1, 
88% in Group 2, 100% in Group 3, and 100% in Group 4. 
Postreperfusion hepatic tissue blood tlow was mark· 
edly improved by the treatment. Treatment signifi. 
cantly attenuated liver enzyme release, lipid peron-
dation, and changes in adenine nucleotides and 
purine catabolites. Structural abnormality of the liver 
after reperfusion was markedly improved by R75231 
treatment, showing better architecture and less neu· 
trophil infiltration. Preischemic administration of a 
nucleoside transport inhibitor ameliorated ischemic 
liver injury due to the positive effects of augmented 
endogenous adenosine, and is applicable clinically 
when the liver is procured from a controlled non-
heartbeating donor. 
Rapid progress in and increased demand for liver trans-
plantation have created a serious organ shortage. The prob-
lem can presently be alleviated by organs procured from 
non-heartbeating donors (1), split liver transplantation (2), 
and living-related grafting (3), while xenotransplantation 
would provide a permanent solution to the shortage of organs 
in the future (4). When transplanting livers obtained from 
non-heartbeating donors, the donor condition and duration of 
warm ischemia become major determinants in graft outcome 
(1). Livers procured under controlled circumstances have 
favorable results, but graft-related complications frequently 
occur if warm ischemia time is prolonged. Livers from uncon-
trolled non-heartbeating donors have poor outcomes. Strate-
gies to protect the liver from damage by warm ischemia, 
hypothermic storage, and/or subsequent reperfusion are es-
sential. 
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Liver ischemia causes progressive degradation of adeno-
sine triphosphate (ATP),* leading to an immense accumula-
tion of purine catabolites in ischemic tissues_ Adenosine, one 
of the intermediary products of the degradation cascade, has 
been known to exert various biological actions (5-10) such as 
increased blood flow, vasodilation, inhibition of free radical 
production, suppression of neutrophil activation, and preven-
tion of platelet aggregation. Upon reoxygenation, adenosine 
becomes an important substrate for ATP resynthesis. How-
ever, adenosine is rapidly deaminated into inosine during 
ischemia and transported out of the ischemic tissues after 
reperfusion, thereby depriving ischemic tissues of ade-
nosine's beneficial effects. In this study, in an attempt to 
establish a strategy for the use of livers from non-heartbea.t-
ing donors, we first tested our hypothesis that augmentation 
of endogenous adenosine by inhibiting its transport with a 
nucleoside transport inhibitor, R75231, attenuates warm 
ischemic liver injury, using a 2-hr total hepatic vascular 
exclusion model. 
MATERIALS AND METHODS 
Animals. Adult female beagle dogs, weighing 8-12 kg, were anes-
thetized, after overnight fasting, with an intravenous injection of 
thiopental sodium, 25 mglkg. They were intubated and the anesthe-
sia was maintained by positive mechanical ventilation with isoflo-
rane, nitrous oxide, and oxygen. The right cartoid artery and the 
right jugular vein were cannulated for arterial blood pressure mon-
itoring and for serial blood collection. 
Operative procedures. After midline laparotomy, the liver was 
isolated by dissecting all of the suspensory ligaments and the retro-
hepatic vena cava. Hepatic vascular exclusion was achieved by cross-
clamping the portal vein and the hepatic artery together with the 
hepatoduodenal ligament, and the suprahepatic vena cava and the 
infrahepatic vena cava separately. Congestion of the mesenteric and 
lower systemic venous beds during hepatic ischemia was decom-
pressed by a venovenous bypass using a centrifugal pump (Biome-
dicus, Minetonka, MN) connected by Tygon tubings to the left fem-
oral vein, the splenic vein and the left jugular vein (Fig. 1). For 
anticoagulation, 50 Ulkg of heparin sodium was administered sys-
temically 5 min before the initiation of hepatic ischemia. After 2·hr 
of ischemia the liver was reperfused, bypass was stopped, and a 
splenectomy was performed. 
Cephamandole nafate 1 g was given intraoperatively and contin-
ued for 3 postoperative days. Animals were followed for two weeks. 
* Abbreviations: ADO. adenosine; ADP, adenosine diphosphate; 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMP. 
adenosine monophosphate; AN. adenine nucleotides; AST, aspartate 
aminotransferase; ATP. adenosine triphosphate; EC, energy charge; 
HX, hypoxanthine; ICG. indocyanine green; INO, inosine; LDH, lac-
tate dehydrogenase; MDA, malondialdehyde; PC, purine catabolites; 
POD, postoperative day; TBA. thiobarbituric acid; X, xanthine. 
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FIGURE 1. Schematic diagram of total hepatic vascular exclusion of 
the canine liver with venovenous bypass. 
Experimental groups. The nucleoside transport inhibitor R75231 
was supplied by the Janssen Research Foundation (Dr. H. Van Belle) 
as a 1 mglml solution. It was dissolved in 20 ml of normal saline at 
doses of 0.1 mglkg (n =6, Group 2), 0.05 mglkg (n = 6, Group 3), and 
0.025 mglkg (n=6, Group 4). R75231 was given to the animals as a 
continuous intravenous infusion for 30 min before liver ischemia. 
Animals given no treatment were used as the control (n=10, Group 
1). Animals were followed for two weeks postoperatively. 
Determinations. The completeness of hepatic vascular interrup-
tion was determined by measuring indocyanine green (lCG) reten-
tion rate and hepatic tissue blood flow. lndocyanine green, 0.5 mglkg, 
was injected intravenously 30 min after the start of hepatic ischemia 
and 20-min lCG retention rate was evaluated spectrophotometri-
cally. Serial measurements of the hepatic tissue blood flow were 
performed by a laser doppler flow meter (Advance Laser Flowmeter, 
ALF21, Advance Company Ltd., Tokyo, Japan) before ischemia, dur-
ing ischemia, and for 60 min after reperfusion. 
Blood samples collected for measurement of aspartate amino-
transferase (AST), alanine aminotransferase (ALT), lactate dehydro-
genase (LDH), alkaline phosphatase (ALP), and total bilirubin were 
analyzed with a Technicon RA500 autoanalyzer (Bayer, Tarrytown, 
NY). Tissue and peripheral blood samples for malondialdehyde 
(MDAl MDA determinations were collected before ischemia, at the 
end of ischemia, and at 15 min and 60 min after reperfusion, and 
malondialdehyde concentrations were determined by the method 
described by Vagi et al. (J 1l. 
Wedge biopsies were repeated before ischemia, at 1 hr and 2 hr 
during ischemia, and 15 min and 60 min after repertiJsion for the 
determination of adenine nucleotides (AN: adenosme triphosphate 
[ATP]; adenosine diphosphase IADP1: and adenOSine monophosphate 
I MJPll. and punne catabolites \ PC: adenosine I ADO I; inosine IINO]; 
hypoxanthine [HX]; and xanthine [X]). The biopsies were divided 
into pieces, immediately frozen (within 15 sec), and stored in liquid 
nitrogen. Measurements were conducted as described before (12) 
using a Waters HPLC system (Waters Chromatography Division, 
Millipore Corp., Milford, MA; Model 510 pumps, Model 484 absor. 
bance module, and Model 717 WISP system), equipped with a tun-
able absorbance detector (Waters Model 484). Energy charge (Ee) 
was calculated by the equation of Atkinson et al. (13). 
For histopathologic analyses, a piece of liver tissue was fixed in 
buffered formalin and stained with hematoxylin and eosin. The 
number of neutrophils that infiltrated into the hepatic tissue was 
counted in 10 random power fields, at a magnification of 100X, with 
sections stained by Leder's neutrophil staining method (14). 
Statistics. Values are expressed as mean:!:SEM. Animal survival 
was determined using the Fisher's exact test. Intra-group analysis 
was performed using the unpaired Student t-test. Inter-group anal-
ysis was performed using ANOV A. When the analysis of variance 
showed a significant difference (P<O.05), a post-hoc test was used to 
determine the P values for each group. 
RESULTS 
Preischemic administration of R75231 caused no signifi-
cant hemodynamic changes. Indocyanine green retention 
rate was 94.8::!::1.2% in Group 1, 94.1::!::1.6% in Group 2, 
95_1::!:: 1.2% in Group 3, and 95.7::!:: 1.5% in Group 4, indicating 
near total ischemia of the liver. 
Immediately after unclamping, all control animals devel-
oped severe swelling and congestion of the liver, which dis-
appeared gradually over 30 to 60 min. In contrast, livers 
treated with R75231 showed smooth revascularization with-
out outflow block, except for transient and mild hepatic 
swelling in Groups 2 and 4. Compared with the control, 
hepatic tissue blood flow after reperfusion was significantly 
augmented in treated animals (Fig. 2). Compared with the 
pre-ischemic level, hepatic tissue blood flow at 5 min after 
reperfusion was 28.8::!::1.9% in Group 1, 58.1::!::3.8% in Group 
2,61.1 ::!:: 2.2% in Group 3, and 56.9 ::!:: 2.3% in Group 4. 
During a two-week follow-up, 7 control dogs died of liver 
failure, 6 within 24 hr and one on postoperative day 10. In the 
treated groups, one animal in Group 2 died of liver failure 12 
hr after reperfusion. Two-week animal survival in the 
treated groups was significantly better than the control: 30% 
in Group 1 versus 83% in Group 2, 100% in Group 3, and 
100% in Group 4. 
In accordance with poor hepatic blood flow and animal 
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FIGURE 2. Tissue blood flow in the liver during ischemia and after 
reperfusion. Values are expressed as a percentage of preischemic 
tissue blood flow level. (. lP<0.05 versus Groups 2. 3. and 4. 
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survival, nontreated Group 1 animals had marked elevation 
of AST (Fig. 3), ALT, and LDH after reperfusion, reaching 
mean peak levels 12 hr afterreperfusion at 11521:!:1014 UIL, 
13563:!:1379 UIL, and 3045:!:633 UIL, respectively. Treat-
ment with R75231 significantly lowered liver enzyme from 
control levels, but there was no statistically significant dif-
ference between treated groups. 
Changes in adenine nucleotide and purine catabolite con-
centrations in liver tissue during ischemia and after reper-
fusion are shown in Table 1. Compared with preischemic 
values, 2 hr of hepatic vascular exclusion in control animals 
induced a 60% decrease in adenine nucleotides, and recipro-
cally, an 800% increase in purine catabolites. In particular, 
ischemia caused a greater than 90% reduction in ATP and 
900% higher production of xanthine. Degradation of adenine 
nucleotides and elevation of purine catabolites by 2 hr of 
ischemia were markedly suppressed by the preischemic ad-
ministration of R75231, especially at a dose of 0.025 mg/kg. 
Although tissue adenosine levels during ischemia were ele-
vated in all treated groups, they were not statistically differ-
ent from the control or between groups. While resynthesis of 
ATP was significantly suppressed after reperfusion in control 
livers, a prompt increase in ATP levels was seen with treated 
livers. Tissue ATP concentration in Group 4 livers was sig-
nificantly higher than ATP levels of Group 1 and Group 2. 
Group 2 livers contained more inosine and hypoxanthine 
than the other treated groups. 
Changes in MDA concentration in liver tissue and plasma 
during ischemia and after reperfusion are shown in Table 2. 
Tissue MDA levels did not show any statistically significant 
differences during ischemia or after reperfusion. However, 
plasma MDA levels increased markedly after reperfusion. 
The increase in plasma MDA was significantly inhibited by 
treatment with R75231. 
Histopathologic examination showed no demonstrable dif-
ferences between the nontreated group and treated groups at 
the end of ischemia. Sporadic single hepatocyte necroses 
were present equally in all groups. After reperfusion, how-
ever, control livers developed significant structural abnor-
malities, including confluenced or bridging hepatocyte necro-
ses, ballooning, sinusoidal congestion and derangement, and 
endothelial cell detachment (Fig. 4A). In contrast, these al-
terations were rarely seen in the treated groups, which had 
well preserved hepatic architecture (Fig. 4B). The number of 
neutrophils infiltrated into postischemic livers 60 min after 
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FIGURE 3. Aspartate aminotransferase levels after reperfusion. 
(*)P<O.05 versus Groups 2. 3. and 4. 
reperfusion was 33.1:!:4.4110 fields in Group 1, 27.B:!:3.1I 
10 fields in Group 2, 14.1:!:2.5/10 fields in Group 3, and 
10.0:!:4.6/l0 fields in Group 4 (P<0.05 Group 3 vs. Group 1 
and Group 2, and Group 4 vs. Group 1). 
DISCUSSION 
Using a critical experimental model of 2-hr hepatic vascu-
lar exclusion in dogs, we demonstrated that inhibition of 
nucleoside transport by R75231 attenuated postreperfusion 
hepatic injury and improved animal survival. Preischemia 
administration of R75231 slowed adenine nucleotide degra-
dation and suppressed purine catabolite accumulation in 
ischemic tissues. After reperfusion, treatment with R75231 
enhanced ATP resynthesis, increased hepatic tissue blood 
flow, inhibited lipid peroxidation, and lessened neutrophil 
infiltration, particularly at the lower doses. 
Since the first description by Drury and Szent-Gyorgy in 
1929 (15), adenosine has been recognized as a local hormone, 
or a "homeostatic metabolite," that regulates the function of 
organs, tissues, and cells in the physiologic state. Over the 
last decade, the importance of adenosine in protecting 
against ischemia and reperfusion injury has caught the at-
tention of many researchers, particularly in the field of car-
diology. Cardiac preconditioning by repeated brief ischemia 
and reperfusion has been shown to improve cardiac function 
and reduce myocyte necrosis after prolonged ischemia (16). 
The mechanisms of protection from preconditioning include 
increased coronary blood flow, vasodilation, suppression of 
free radical generation, preservation of high energy stores, 
enhancement of stress protein, and inhibition of neutrophil 
and platelet activation (17). Most of these properties have 
been attributed to the biological action of adenosine (5-10) 
and adenosine-related molecular events, such as modulation 
of adenosine receptors (18), ATP sensitive potassium channel 
(19), and regulatory G proteins (20). 
Similar to ischemic preconditioning, systemic or local ad-
ministration of exogenous adenosine before ischemia, before 
reperfusion, or both, has been reported to attenuate ischemia 
and reperfusion injury (21-23); however, exogenous adeno-
sine supplementation also has disadvantages. Exogenous 
adenosine disappears rapidly from the circulation, due to its 
extremely short half-life of a few seconds in humans (24) and 
a few minutes in dogs (25). Adenosine causes systemic ad-
verse effects, including hypotension, renal impairment, and 
reduction of hepatic blood flow, if the dose is excessive. In 
contrast, augmentation of endogenous adenosine concentra-
tion by the regulation of adenosine metabolism is a safe and 
promising alternative, because it takes advantage of the ben-
eficial effects of adenosine within the organ and only when it 
becomes ischemic, in a site-specific and event-specific man-
ner. Regulation of adenosine metabolism can be achieved 
using nucleoside transport inhibitors (26). adenosine de ami-
nase inhibitors (27), and 5-aminoimidazole-4-carboxamide ri-
boside (AleA roboside or acadesine) (28) . 
R75231 is a novel nucleoside transport inhibitor, which is 
more potent and has a longer duration of action and a higher 
bioavailability than mioflazine. lidoflazine. dipyridamole, ni-
trobenzyl-thioinosine. and other inhibitors. The protective 
effect of this agent against ischemia and reperfusion injury 
has been reported with the heart (29-31) and the kidney (32) 
in humans and experimental animals. The mechanism of 
adenosine metabolism and drug action has been well inves-
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TABLE 1. Tissue concentrations of adenine nucleotides and purine catabolites in canine livers during ischemia and after reperfusion 
Dose Tan ATP ADP AMP ADO INO HX X Group (mg/kgJ EC (nmollmg (nmollmg (nmollmg (nmollmg (nmollmg (nmollmg (nmollmg (nmollmg protein) protein) protein) protein) protein) protein) protein) protein) 
Normal 0.82:!:0.01 30.4:!:2.1 21.8:!:2.0 6.9:!:0.7 1. 7:!:0.3 0.99:!:0.02 0.18:!:0.08 0.84:!:0.12 0.06:!:0.03 
1 hr of warm ischemia: 
Group 1 0 0.32:!:0.02 25.2:!:3.5 4.7:!:0.7 6.8:!:1.0 13.7:!:2.1 0.31:!:0.07 0.95:!:0.07 2.85:!:0.29 2.53:!:0.28 
Group 2 0.1 0.30:!:0.03 25.5:!:1.8 4.3:!:0.5 6.4:!:0.4 14.8:!:1.6 0.64:!:0.21 0.75:!:0.24 1.42:!:0.12" 1.71:!:0.34 
Group 3 0.05 0.30±0.03 23.1:!:2.5 4.1:!:0.8 5.6:!:0.8 13.5:!:1.6 0.62:!:0.17 1.04:!:0.18 1.41:!:0.39" 2.20:!:0.36 
Group 4 0.025 0.34:!:0.02 19.7:!:1.2 4.2:!:0.3 4.9:!:0.3 10.5:!:0.8 0.18:!:0.03" 0.65:!:0.15 0.80:!:0.14" 1.65±0.30" 
2 hr of warm ischemia: 
Group 1 0 0.22±0.02 13.0±0.7 1.6±0.3 2.6±0.2 8.7±0.5 0.26±0.05 0.67:!:0.17 3.37±0.22 5.33±0.37 
Group 2 0.1 0.23±0.02 18.2:!:1.0" 2.5±0.3 3.5±0.4 12.1:!:0.7" 0.54±0.15 0.81:!:0.22 1.94:!:0.38" 2.83±0.44" 
Group 3 0.05 0.26±0.03 17.h2.0" 2.8:!:0.5 3.7:!:0.5" 11. I:!: 1.4 0.44±0.13 0.95:!:0.20 1.49:!:0.19" 3.31:!:0.49" 
Group 4 0.025 0.27:!:0.04 17.9:!:0.7" 3.0:!:0.7" 3.8:!:0.44 11.1±0.7 0.32:!:0.1O 0.59:!:0.08 1.37:!:0.22" 2.86:!:0.30" 
15 min after reperfusion: 
Group 1 0 0.72:!:0.04 12.1±2.1 7.2±1.5 3.5:!:0.6 1.3:!:0.1 0.16:!:0.04 0.32:!:0.10 1.lO:!:0.21 0.42:!:0.23 
Group 2 0.1 0.72±0.04 18.3:!:3.0 10.8±1.9 5.0:!:1.1 2.5±0.5 0.15±0.04 0.55:!:0.2 0.72:!:0.21 0.14:!:0.09 
Group 3 0.05 0.82:!:0.02" 17.9:!:1.5 12.9:!:1.1" 3.7:!:0.5 1.3±0.2 0.14:!:0.03 0.25±0.03 0.36:!:0.10" 0.04:!:0.044 
Group 4 0.025 0.80:!:0.02 16.7:!:1.8 11.7±1.3" 3.4:!:0.6 1.5:!:0.3 0.08:!:0.01 0.21±0.04 0.08:!:0.014 0.04:!:0.044 
60 min after reperfusion: 
Group 1 0 0.83:!:0.01 12.2:!:0.9 8.9±0.8 2.4±0.3 0.8:!:0.1 0.08:!:0.02 0.28:!:0.09 0.78:!:0.14 0.26:!:0.06 
Group 2 0.1 0.80:!:0.04 16.6:!:3.3 10.9:!:2.5 4.3:!:1.4 1.5:!:0.5 0.12:!:0.03 0.20:!:0.04 0.60±0.25 0.02:!:0.01" 
Group 3 0.05 0.88±0.01 16.7:!:0.5 13.4:!:0.4 2.7:!:0.2 0.7:!:0.1 0.10:!:0.02 0.16:!:0.03 0.13:!:0.054 O.OO:!:O.OO" 
Group 4 0.025 0.86:!:0.02 18.8:!:1.84 15.1:!:1.64 2.6±0.3 1.1±0.3 0.07:!:0.01 0.22:!:0.03 0.10:!:0.03" O.OO:!:O.OO" 
" P<0.05 vs. Group 1. 
TABLE 2. Tissue and plasma concentration of malondialdehyde during liver ischemia and after reperfusion 
During ischemia After reperfusion 
1hr 2hr 15 min 60 min 
Tissue MDA (nmoL'mg protein)" 
Group 1 1.375:!:0.364 
Group 2 0.875:!:0.083 
Group 3 0.905:!:0.086 
Group 4 0.607:!:0.059 
0.970:!:0.081 
0.735:!:0.077 
1.040:!:0.124 
0.682:!:0.040 
0.488:!:0.113 
0.517:!:0.135 
0.757:!:0.107 
0.479:!:0.063 
0.505:!:0.091 
0.426:!:0.102 
0.568:!:0.072 
0.453:!:0.053 
Plasma MDA (J.LmoliL)b 
Group 1 
Group 2 
Group 3 
Group 4 
0.777:!:0.088 
0.844:!:0.072 
0.764:!:0.120 
0.688:!:0.060 
1.252:!:0.127 
0.904:!:0.079" 
0.850:!:0.061c 
0.728:!:0.049" 
1.237:!:0.161 
1.006:!:0.160c 
0.816:!:0.072" 
0.71O:!:0.097C 
4 Normal tissue MDA level = 1.071 :!: 0.098 nmoL'mg protein. 
b Normal plasma MDA level = 0.754 :!: 0.051 J.LffioliL. 
c P < 0.05 VS. Group 1. 
tigated in the heart by Van Belle and associates (33, 34). 
According to Van Belle, AMP, which increases in ischemic 
tissues from the degradation of ATP and ADP, is dephospho-
rilized to adenosine by cytosolic 5' -nucleotidase within the 
myocytes. and. preferentially, by membrane-bound ecto 5'-
nucleotide in the interstitial space after leaving the myocytes 
by diffusion. The majority of adenosine in the interstitial 
space is taken up, facilitated by nucleoside transport pro-
teins. into the endothelial cells. where adenosine is rapidly 
converted to inosine by adenosine diaminase, and then. to 
hypoxanthine and xanthine. R75231 inhibits adenosine 
transport. suppresses further catabolism of adenosine in the 
endothelial cells. enhances adenosme concentration in the 
mterstltial space. and delays adenosine wash-out after reper-
fusion. thereby maximizing the salutary effects of adenosine 
during ischemia and reperfusion. 
In this study, R75231 significantly increased adenine nu-
cleotide levels and decreased purine catabolite levels in the 
ischemic tissues compared to the control, but tissue adeno-
sine levels were only slightly and insignificantly enhanced. 
This finding is in contrast to results obtained with hearts 
(29-31), which showed marked elevation of adenosine in 
cardiac tissues (14 times) and in the coronary effiuent (7 
times). Because cardiac myocytes lack adenosine deaminase 
(35), the transport and deamination of adenosine in the en-
dothelial cells serves as a major route of adenosine metabo-
lism in the heart. Thus. the inhibition of adenosine transport 
appears to Induce a profound elevation of adenosine levels in 
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FIGURE 4. Histopathology of the control liver (A) and R75231 treated 
liver (B) at 60 min after reperfusion (H&E; X200). 
cardiac tissues and the interstitium. However, adenosine 
metabolism in the liver consists of deamination in hepato-
cytes and adenosine transport and catabolism in endothelial 
cells. Isolated purified hepatocytes have been shown to pro-
duce increasing amounts of nucleosides and purine catabo-
lites in relation to the duration of anoxia (36). In our study, 
R75231 treatment definitely decreased purine catabolite lev-
els in the ischemic livers, indicating nucleoside transport 
inhibition and decreased production of purine catabolites in 
the endothelial cells. Although not measured, interstitial 
adenosine concentration in liver tissues would be increased 
by treatment. After reperfusion, R75231 administration en-
hanced resynthesis of high energy phosphate. possibly by 
increased amounts of substrate in liver tissues at the end of 
2·hr ischemia. In an isolated perfusion system, Palombo et al. 
(37) reported enhanced high energy phosphate resynthesis 
by adenosine supplementation after reperfusion of rat livers 
preserved with UW solution. 
Preischemic administration of R75231 improved hepatic 
tissue blood flow after reperfusion. which is thought to result 
from three interrelating mechanisms: vasodilation. the inhi-
bition of neutrophil infiltration. and the preservation of mi-
crovasculatures. 
Adenosine exerts vasodilatory action not only by acting 
directly on vascular smooth muscles. but also by modulation 
of vascular endothelial cells which synthesize and secrete 
various vasodilatory substances (such as nitric oxide and 
prostacyclin) and vasoconstrictive substances (such as endo-
thelin and thromboxane A2). McKie et al. (5) reported that 
increased blood flow in the gastrointestinal tract and the 
kidney after adenosine administration was suppressed by 
nitro-L-arginine methy ester, a competitive inhibitor of nitric 
oxide synthetase. Endothelin release from ischemic myocar-
dium of dogs was inhibited by administration of endogenous 
adenosine during the early reperfusion period (23). Adeno-
sine and R75231 suppressed endothelin levels in the hepatic 
venous blood in separate liver ischemia experiments (unpub-
lished data). 
R75231 reduced the number of neutrophils infiltrating the 
postischemic livers. It has been shown that exogenous aden-
osine inhibits accumulation, adherence, and activation of 
neutrophils by attenuating the upregulation of Mac-l expres-
sion via stimulation of A2 receptor on neutrophil membranes 
(9) and suppresses superoxide generation (6). Thus, the "no-
reflow" caused by neutrophil plugging the microvasculature 
of postischemic livers is prevented. 
Finally, nucleoside transport inhibition appears to prevent 
microvasculature damage by suppressing superoxide produc-
tion in the endothelial cells and Kupffer cells during isch-
emia, and in these cells and neutrophils after reperfusion. In 
this study, both hypoxanthine and xanthine were signifi-
cantly elevated in ischemic control livers. Hypoxanthine is 
catabolized to xanthine, producing superoxide anions, by 
xanthine oxidase that is converted from xanthine reductase 
during ischemia. Recently, Brass et al. (38) have shown that 
in anoxic isolated rat liver cells, the conversion of xanthine 
dehydrogenase to xanthine oxidase occurs mostly actively in 
Kupffer cells, moderately in endothelial cells, and weakly in 
hepatocytes. Studies using ultrastructural enzyme histo-
chemistry (39) and long-acting superoxide dismustase (40) 
have supported his findings. Treatment with R75231 inhib-
ited hypoxanthine and xanthine elevations during ischemia, 
which suggests reduced production of superoxide in Kupffer 
cells and endothelial cells. Inhibition of free radical genera-
tion by adenosine in Kupffer cells and neutrophils after 
reperfusion has been documented (6, 8, 41). 
Previous studies and this experiment indicate that free 
radical generation and the resulting lipid peroxidation are 
mlijor causes of ischemia and reperfusion injury of the liver; 
however, we could not detect MDA in tissue homogenate by 
thiobarbituric acid (TBA) reaction during ischemia, and even 
after reperfusion. This may reflect a problem with sensitivity 
with the assay method (42). It may also suggest that lipid 
peroxidation occurs mainly in nonparenchymal cells rather 
than the hepatocytes, and that it can not be detected with 
tissue homogenates because more than 90% of protein in the 
homogenate is derived from hepatocytes. Walsh et al. (43) 
reported the exclusive presence of conjugated dienes in non-
parenchymal cell fractions isolated from the rat livers sub-
jected to warm ischemia. 
R75231 can be used clinically for the procurement of or-
gans from non-heartbeating donors. Non-heartbeating do-
nors have been classified into four categories (44): dead on 
arrival (category 1); unsuccessful resuscitation (category 2); 
awaiting cardiac arrest (category 3); and cardiac arrest while 
brain dead (category 4). At the very least R75231 treatment 
would be indicated for category 3 donors. R75231 would be 
administered intravenously before the termination of venti-
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latory support, as heparin is given for anticoagulation (1). 
Even donors in category 2 and category 4 would benefit from 
R75231 treatment if treatment is started during resuscita-
tion. This could safely be done since R75231 did not cause 
any significant hemodynamic changes. More important, 
R75231 can be added to the preservation solution to prevent 
further degradation of adenosine during cold storage and/or 
given to the recipient immediately before reperfusion to in-
hibit adenosine uptake by the erythrocytes and to delay its 
washout from ischemic tissues. The beneficial effect of the 
last approach has been shown in canine heart preservation 
and transplantation (29, 46, 47), and further study is being 
conducted at our laboratory using a canine liver transplan-
tation model. 
In summary, preischemic administration of the nucleoside 
transport inhibitor, R75231, attenuated postreperfusion liver 
injury, apparently from the positive effect of augmented en-
dogenous adenosine. However, it was intriguing that we did 
not see much difference in the determinants depending upon 
the dose of R75231. This may indicated that the positive 
effect of adenosine is not related to the amount of adenosine 
in the interstitial space, but to the adenosine receptors that 
have different affinities to adenosine. Studies that are also 
currently underway with various adenosine receptor agonists 
and antagonists are required to elucidate the role of adeno-
sine receptors in ischemia. 
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TACROLIMUS RESCUE THERAPY FOR RENAL ALLOGRAFT 
REJECTION -FIVE-YEAR EXPERIENCE1 
MARK L. JORDAN,2.3 ROBERT NARAGHI,3 RON SHAPIRO,4 DEIDRE SMITH,3.5 CARLOS A. VIVAS,3 
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Division of Urologic Surgery and Renal Transplantation and the Pittsburgh Transplantation Institute, Department of 
Surgery, University of Pittsburgh Medical Center Pittsburgh, Pennsylvania 15213 
Over the 5 year period from 7/1411989 until 5/2411994, 
we have attempted graft salvage with tacrolimus con-
version in a total of 169 patients (median age 33 years, 
range 2-75 years) with ongoing rejection on baseline 
CsA immunosuppression after failure of high dose cor-
ticosteroids and/or antilymphocyte preparations to re-
1 Presented at the 22nd Annual Meeting of the American Society 
of Transplant Surgeons. May 29 -31, 1996. Dallas. TX. 
2 Address correspondence to Mark L. Jordan. M.D., Suite 700. 
Liliane Kaufmann Building, 3471 Fifth Ave .. Pittsburgh, PA 15213. 
3 Division of Urologic Surgery and Renal Transplantation. Univer-
sity of Pittsburgh Medical Center. Pittsburgh, PA. 
• Pittsburgh Transplantation Institute. Department of Surgery. 
University of Pittsburgh Medical Center. Pittsburgh, PA. 
<; Supported in part by a grant from Fujisawa U.S.A.. Inc. 
verse rejection. The indications for conversion to ta-
crolimus were ongoing, biopsy confirmed rejection in 
all patients. The median interval to tacrolimus conver-
sion was 2 months (range 2 days to 55 months; mean 
4.3±2_6 months) after transplantation. All patients had 
failed high dose corticosteroid therapy and 144 (85%) 
of the 169 patients had received at least one course of 
an antilymphocyte preparation plus high dose corti-
costeroid therapy prior to conversion. Twenty-eight 
patients (17%) were dialysis-dependent at the time of 
conversion owing to the severity of rejection. With a 
mean follow-up of 30.0±2.4 months (median 36.5 
months. range 12-62 months), 125 of 169 patients (74%) 
have been successfully rescued and still have func-
tioning grafts with a mean serum creatinine (SCR) of 
2.3± 1.1 mgldl. Of the 144 patients previously treated 
